Emergence of smart cardiac monitors, heavy burden of heart ailments and the rise in FDA approvals can also translate into considerable revenue generation in the next couple of years. Besides, the heightened preference for cost-effective electrocardiogram devices, and firms spending generously on R&D activities to come up with systems with better features should also favor the global market in the following years. Players frequently make strategic moves such as production expansion, technical innovations, and acquisition to improve their market rankings. Companies are also working on leveraging the potential of artificial intelligence, IoT and big data by integrating these technologies into their devices, to enhance their appeal.

Segmentation

Top segments considered in the study of the arrhythmia monitoring devices market include device type, application, and end user.

Device types analyzed in the report include mobile cardiac telemetry (MCT) devices, resting ECG, implantable cardiac monitor (ICM), Holter monitor, event monitor, among others.

Conduction disorders, premature ventricular contractions (PVC), tachycardia, ventricular fibrillation (V-fib), bradycardia and atrial fibrillation (A-fib) are some of the major applications covered in the report.

Home care settings, diagnostic centers, ambulatory surgery centers (ASC) and hospitals & clinics, are some of the top end-users in the market. The leading spot has been procured by the hospitals and clinics segment, which touched USD 1,740.0 Million in 2018.

Regional Status

Arrhythmia monitoring devices industry can be regionally divided into Europe, Asia Pacific (APAC), MEA or Middle East and Africa as well as the Americas.

America has emerged as the most profitable market, on account of the easy availability of highly innovative and effective options for arrhythmia, such as artificial pacemakers, antiarrhythmic drugs and implanted defibrillators. The region’s favorable reimbursement policies and the vast pool of renowned firms that spend significantly on rigorous R&D activities also enhance the market share.

Europe is currently the second most lucrative market, given that the adoption rate of cardiac arrhythmia monitors in the region is significantly high in line with the escalating cases of cardiac disorders. In 2018, the lead was taken by Spain in the region, accounting for a share of 5.5% in view of the surging use of smartphone applications bridging the communication gap between patients and doctors. Moreover, with clinics and hospitals striving to include arrhythmia care in routine treatment procedures, the European market is bound to fare well in the years to come.

Asia Pacific should progress at the fastest rate in the following years, as a result of the exploding population and the continuous surge in the use of latest technologies like wearables such as fitness monitors, mobile monitoring systems and fabric monitoring systems. Soaring preference for compact, home‐based, and portable monitoring devices along with the improving reimbursement scenario will also benefit the APAC market in subsequent years.

Prominent Contenders

Some of the affluent firms analyzed in the MRFR market study are Spacelabs Healthcare (US), Biotronik (Germany), Abbott Laboratories (US), Medtronic plc (Ireland), Alive Cor, Inc. (US), BioTelemetry, Inc. (US), Fukuda Denshi Co. Ltd (Japan), Applied Cardiac Systems Inc. (US), Nihon Kohden Corporation (Japan), GE Healthcare (US), and more.